Dropping with the temps: Cool deals on CST mAbs | Learn More >>
SOCS3 (L210) Antibody
Primary Antibodies

SOCS3 (L210) Antibody #2932

This product is discontinued


Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

SOCS3 (L210) Antibody detects endogenous levels of total SOCS3 protein.

Species predicted to react based on 100% sequence homology:

Monkey, Bovine, Dog

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu210 of SOCS3. Antibodies were purified by protein A and peptide affinity chromatography.

The suppressor of cytokine signaling (SOCS) family members are negative regulators of cytokine signal transduction that inhibit the Jak/Stat pathway (1-3). The SOCS family consists of at least 8 members including the originally identified cytokine-inducible SH2-containing protein (CIS1), as well as SOCS1-7. Each SOCS family member contains a central SH2 domain and a conserved carboxy-terminal motif designated as the SOCS box. These proteins are important regulators of cytokine signaling, proliferation, differentiation, and immune responses.

Low levels of SOCS3 are observed in lung, spleen and thymus and, like other SOCS family members, its expression is rapidly induced by a number of factors including interleukins, EPO, IFN-γ, CSF and TNF-α (4). SOCS3 uses its SH2 domain to bind activated Jaks and their cognate receptors to provide negative feedback inhibition. In addition to the initially described inducers of SOCS3 expression, subsequent studies have described SOCS3-mediated negative feedback inhibition for leptin (5), GH (6), chemokine receptors (7), insulin (8), and certain pathogens (9,10). SOCS3 deletion results in embryonic lethality with placental insufficiency (11). SOCS3 signaling has been linked pathologically to allergic responses (12), inflammatory disease (13), endotoxic shock (14), wound repair (15), and obesity (16,17).

  1. Alexander, W.S. et al. (1999) J Leukoc Biol 66, 588-92.
  2. Chen, X.P. et al. (2000) Immunity 13, 287-90.
  3. Hilton, D.J. et al. (1998) Proc Natl Acad Sci USA 95, 114-9.
  4. Bjørbaek, C. et al. (1998) Mol Cell 1, 619-25.
  5. Adams, T.E. et al. (1998) J Biol Chem 273, 1285-7.
  6. Soriano, S.F. et al. (2002) J Exp Med 196, 311-21.
  7. Emanuelli, B. et al. (2000) J Biol Chem 275, 15985-91.
  8. Stoiber, D. et al. (1999) J Immunol 163, 2640-7.
  9. Stoiber, D. et al. (2001) J Immunol 166, 466-72.
  10. Starr, R. et al. (1997) Nature 387, 917-21.
  11. Roberts, A.W. et al. (2001) Proc Natl Acad Sci U S A 98, 9324-9.
  12. Seki, Y. et al. (2003) Nat Med 9, 1047-54.
  13. Shouda, T. et al. (2001) J Clin Invest 108, 1781-8.
  14. Fang, M. et al. (2005) Cell Mol Immunol 2, 373-7.
  15. Goren, I. et al. (2006) J Invest Dermatol 126, 477-85.
  16. Mori, H. et al. (2004) Nat Med 10, 739-43.
  17. Howard, J.K. et al. (2004) Nat Med 10, 734-8.
Entrez-Gene Id
Swiss-Prot Acc.
For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Upstream / Downstream


Explore pathways related to this product.